| 8:00 — 9:00 AM | Registration | |
| 9:00 — 9:45 AM | Session #1 — Welcome and Introductory Remarks
Dr. Joe Harford, NCI Mr. Koji Nakanishi, JSPS Dr. M. Terada (Coordinator) |
|
| 9:45 — 10:30 AM | Coffee break and cake to celebrate 30 years of US-Japan Cooperation on Cancer Research
Keynote Speakers — |
|
| 10:30 — 11:15 AM | Dr. Robert Weinberg (Whitehead Inst./MIT, Cambridge, MA): Cellular Mechanisms Leading to Human Tumor Formation | |
| 11:15 — 12:00 PM | Dr. Julie Buring (Brigham and Women’s Hospital, Boston, MA): Discrepancies between observational studies and randomized trials: What lessons can we learn— | |
| 12:00 — 1:30 PM | Lunch | |
| Session #2 — Molecular Cancer Therapeutics: Epidemiology and Population Science Chairs: Dr. Ed Trapido and Dr. Tomoyuki Kitagawa |
||
| 1:30 — 2:00 PM | Dr. Naoko Sueoka (Saga Univ., Faculty of Medicine): Heterogeneous nuclear ribonucleoprotein B1 as a new parameter for early detection and chemoprevention of human lung cancer | |
| 2:00 — 2:30 PM | Dr. Mark Shriver (Penn State Univ., University Park, PA): Measuring and using ancestry to study the genetics of complex diseases | |
| 3:00 — 3:30 PM | Dr. Tetsuya Kamataki (Graduate Sch. of Pharmaceutical Science, Hokkaido Univ.): CYD2A6 genetic polymorphism as an important factor determining the risk of tobacco-related cancer | |
| 3:30 — 3:45 PM | Coffee break | |
| 3:45 — 4:15 PM | Dr. Michael Antoni (Univ. of Miami, Coral Gables, FL): Effects of Stress Management Intervention on Quality of Life and Physiological Functioning in Women with Breast Cancer | |
| 4:15 — 4:45 PM | Dr. Shunro Sonoda (Kagoshima Univ., Faculty of Medicine): HLA-A*26, HLA-B*4002, HLA-B*4006,m and HLA-B*4801 alleles predispose to adult T cell leukemia: the limited recognition of HTLV type 1 tax peptide anchor motifs and epitopies to generate anti-HTLVtype 1 tax CD8(+) cytotoxic T lymphocytes | |
| 4:45 — 5:15 PM | Dr. Gary Schwartz (Comprehensive Ca. Ctr. At Wake Forest Univ., Winston-Salem, NC): Looking on the sunny side: Prostate cancer chemoprevention with vitamin D | |
| Session #3 - Molecular cancer Therapeutics: Clinical Science Chairs: Dr. Michaele Christian and Dr. Takashi Tsuruo |
||
| 8:30 — 9:00 AM | Dr. Peter Jones (Norris Comprehensive Can. Ctr., USC, Los Angeles, CA): Epigenetic therapy | |
| 9:00 — 9:30 AM | Dr. Yoichi Furukawa (Inst. of Medical Science, Univ. of Tokyo): Identification and characterization of novel molecular targets for treatment of human cancer | |
| 9:30 — 10:00 AM | Dr. Hiroyuki Seimiya (Cancer Chemotherapy Ctr., JFCR): Mechanisms for telomere length regulation as anticancer molecular target | |
| 10:00 — 10:15 AM | Coffee break | |
| 10:15 — 10:45 AM | Dr. Neal Rosen (MSKCC, New York, NY): Hsp90: Development of an unexpected therapeutic target | |
| 10:45 — 11:15 AM | Dr. Yoshiro Niitsu (Sapporo Med. Univ., Sapporo): A novel AML therapy targeting VLA4/fibronectin interaction | |
| 11:15 — 11:45 AM | Dr. Gregg Semenza (Johns Hopkins Univ., Baltimore, MD): HIF-1alpha as a therapeutic target | |
| 11:45 — 1:00 PM | LUNCH | |
| Session #4 — Molecular cancer Therapeutics: Basic Science Chairs: Dr. Snorri Thorgeirsson and Dr. Masaaki Terada |
||
| 1:00 — 1:30 PM | Dr. Michiyuki Matsuda (Res. Inst. for Microbial Diseases, Osaka): Growth stimulating pathways visualized by probes based on the principle of fluorescence resonance energy transfer | |
| 1:30 — 2:00 PM | Dr. Anita Roberts (NCI, Bethesda, MD): The two faces of TGF-beta in carcinogenesis | |
| 2:00 — 2:30 PM | Dr. Keiji Wakabayashi (Natl. Cancer Ctr. Res. Inst.): Mono (ADP-ribosyl)action of N2 position of guanine in DNA by an apoptosis-inducing protein, pierisin-1, from cabbage butterfly | |
| 2:30 — 2:45 PM | Coffee break | |
| 2:45 — 3:15 PM | Dr. Jeffrey M. Rosen (Baylor College of Medicine, Houston, TX): Stem cells and cancer | |
| 3:15 — 3:45 PM | Dr. Yukiko Gotch (Univ. of Tokyo): Regulation of cell death by phosphorylation | |
| 3:45 — 4:15 PM | Dr. Steven Rosenberg (NCI, Bethesda, MD): Adoptive-cell-therapy for the treatment of patients with cancer | |
| 4:15 — 4:30 PM | Closing Remarks and Adjournment | |